The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease
Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths in the USA. Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD. Despite a plethora of studies showing the benefit of aspirin in secondary prevention of cardiovascular events, debate remains regarding the optimal dose due to relatively small studies that had disparate results when comparing patients taking different aspirin dosages. More recently, aspirin dosing has been thoroughly studied in the CAD population with concomitant therapy (such as P2Y12 inhibitors); however, patients in these studies were not randomized to aspirin dose. No randomized controlled trial has directly measured aspirin dosages in a population of patients with established coronary artery disease. In 2015, the Patient-Centered Outcomes Research Institute (PCORI) developed a network, called PCORnet, that includes patient-powered research networks (PPRN) and clinical data research networks (CDRN). The main objective of PCORnet is to conduct widely generalizable observational studies and clinical trials (including large, pragmatic clinical trials) at a low cost. The first clinical trial, called Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE), will randomly assign 20,000 subjects with established coronary heart disease to either low dose (81 mg) or high dose (325 mg) and should be able to finally answer which dosage of aspirin is best for patients with established cardiovascular disease.
KeywordsAspirin Coronary artery disease Secondary prevention Myocardial infarction
American College of Cardiology Foundation
acute coronary syndrome
American Heart Association
anisoylated plasminogen streptokinase activator complex
Antiplatelet Trialists’ Collaboration
Antithrombotic Trialists’ Collaboration
coronary artery bypass graft
coronary artery disease
clinical data research networks
Global Use of Strategies to Open Occluded Arteries
major adverse cardiovascular event
non-ST-elevation myocardial infarction
Patient Centered Outcomes Research Institute
Practice Innovation and Clinical Excellence
patient-powered research networks
randomized controlled trial
stable ischemic heart disease
ST-elevation myocardial infarction
transient ischemic attack
Thrombolysis in Myocardial Infarction
tissue plasminogen activator
TReatment with ADP receptor iNhibitorS: Longitudinal, Assessment of Treatment Patterns and Events after Acute, Coronary Syndrome
Compliance with Ethics Standards
Conflict of Interest
Abigail Johnston declares that she has no conflict of interest.
W. Schuyler Jones reports research grants from Agency for Healthcare Research and Quality, AstraZeneca, American Heart Association, Boston Scientific Corporation, Bristol-Myers Squibb, and Patient-Centered Outcomes Research Institute; and honorarium/other from American College of Radiology and Daiichi Sankyo.
Adrian F. Hernandez reports research grants from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Glaxo SmithKline, Merck, and Portola Pharmaceuticals; and consulting from Amgen, AstraZeneca, Bayer, Eli Lilly, Gilead, Glaxo SmithKline, Janssen, Merck, Novartis, Ortho-McNeil, Pfizer, Pluristem Therapeutics, and MyoKardia.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
ADAPTABLE is being funded by the Patient-Centered Outcomes Research Institute. Dr. Hernandez serves as the PCORnet Coordinating Center Principal Investigator.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322. The most recent statistics issued by the American Heart Association indicate the high prevalence of coronary heart disease and the wide variation in aspirin treatment across the US. CrossRefPubMedGoogle Scholar
- 4.ISIS-2 Investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–60.Google Scholar
- 5.Soni A. Aspirin use among the adult U.S. noninstitutionalized population, with and without indicators of heart disease, 2005. Statistical Brief #179. Rockville: Agency for Healthcare Research and Quality; 2007. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179.pdf.
- 7.Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108(14):1682–7.CrossRefPubMedGoogle Scholar
- 10.••Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;7(5):701–7. This study shows the variation in aspirin dosing patterns across the United States in patients post- acute coronary syndrome.CrossRefPubMedGoogle Scholar
- 24.Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233–43.CrossRefPubMedGoogle Scholar
- 25.Xian Y, Wang TY, McCoy LA, et al. Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation 2015;132(3):174–81.Google Scholar
- 26.Kohli P, Udell JA, Murphy SA, et al. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON–TIMI 38 study (Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014;63(3):225–32.CrossRefPubMedGoogle Scholar
- 28.Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany “Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified”. Thromb Haemost. 2011;105(5):763–5.CrossRefPubMedGoogle Scholar
- 31.Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76(1):142–54.CrossRefPubMedGoogle Scholar
- 34.Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.CrossRefPubMedGoogle Scholar
- 35.Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.CrossRefPubMedGoogle Scholar
- 37.••ADAPTABLE Home- Adaptable. Retrieved from http://theaspirinstudy.org. This study is a large, multicenter randomized clinical trial addressing optimal aspirin dosing in secondary prevention in patients with cardiovascular disease.